Education and Training
Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder
Overactive bladder (OAB) is a highly prevalent disease process that, when refractory to oral medication therapy, can be effectively managed with injection of botulinum toxin A (BTA) into the detrusor muscle of the bladder. However, the traditional procedure requires a cystoscope inserted into the bladder which can be painful and is associated with a risk of urinary tract infection. The purpose of this study is to determine if transvaginal injection of BTA into the detrusor muscle of the bladder wall is feasible to perform, and efficacious for the treatment of refractory overactive bladder.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Transvaginal botulinum toxin A (BTA) injection
Eligibility
Inclusion Criteria:
- Females with overactive bladder
- Females who are considering intradetrusor botulinum toxin A chemodenervation for the
treatment of refractory overactive bladder
Exclusion Criteria:
- Overactive bladder caused by neurological condition (i.e. spinal cord injury, multiple
sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, etc.)
- Predominance of stress urinary incontinence as reported by the patient
- Involvement in other studies with potentially overlapping indications or symptoms
- Patients who are unable to undergo a transvaginal ultrasound intervention as a result
of anatomic barriers or discomfort will be excluded from enrollment
- Patients known to be pregnant or breastfeeding
- Known allergy to botulinum toxin A injection therapy
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Female
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting